19 results
6-K
EX-99.1
CLLS
Cellectis
31 May 23
Current report (foreign)
4:58pm
and models recapitulating antigen escape, a current challenge in the field that can lead to treatment failure. Moreover, UCART20x22 is developed … in a dose dependent manner, with both doses of 3 and 10 million CAR T-cells achieving complete tumor clearance.
Xenograft models mimicking antigen escape
6-K
EX-99.1
CLLS
Cellectis
3 Nov 22
Current report (foreign)
5:09pm
of resistance to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL), such as single-antigen escape or tumor heterogeneity
6-K/A
EX-99.1
CLLS
Cellectis
31 Aug 22
Current report (foreign) (amended)
4:22pm
of resistance to CART-cell
therapies in relapsed or refractoryNon-Hodgkin
Lymphoma (r/r NHL), such as single-antigen escape or tumor heterogeneity.
On April 26
6-K
EX-99.1
CLLS
Cellectis
4 Aug 22
Current report (foreign)
4:39pm
to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL), such as single-antigen escape or tumor heterogeneity.
On April 26
6-K
EX-99.1
ymqwx gye
12 May 22
Current report (foreign)
4:48pm
6-K
EX-99.1
f88dn acy
8 Apr 22
Current report (foreign)
4:30pm
6-K
EX-99.1
lvi8j5 e5
3 Mar 22
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
4:55pm
6-K
EX-99.1
cmen1v
14 Jun 21
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
4:30pm
20-F
78lo2qyp
21 Mar 16
Annual report (foreign)
12:00am
F-1
lku3fuigi aw
20 Feb 15
Registration statement (foreign)
12:00am
DRS/A
rhuh6rod8hq604e194u
27 Jan 15
Draft registration statement (amended)
12:00am
DRS
opg3pd2m ww4ifwmq
19 Dec 14
Draft registration statement
12:00am
- Prev
- 1
- Next